

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 October 2023 (12.10.2023)



(10) International Publication Number
WO 2023/196980 A1

(51) International Patent Classification:

C12N 5/078 (2010.01) C07K 14/725 (2006.01)
C12N 5/074 (2010.01) C07K 14/735 (2006.01)
C07K 14/705 (2006.01) C07K 16/28 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2023/065535

(22) International Filing Date:

07 April 2023 (07.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/328,730 07 April 2022 (07.04.2022) US
63/341,970 13 May 2022 (13.05.2022) US
63/382,620 07 November 2022 (07.11.2022) US
63/386,880 09 December 2022 (09.12.2022) US

(71) Applicant: **FATE THERAPEUTICS, INC.** [US/US];
12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(72) Inventors: **VALAMEHR, Bahram**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **GOODRIDGE, Jode**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US). **WILLIAMS, Alan**; 12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(74) Agent: **GIERING, Jeffery, C.** et al.; Greenberg Traurig, LLP, 77 West Wacker Drive, Suite 3100, Chicago, IL 606101 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: STEALTH STRATEGY ENGAGING IMMUNE RECOGNITION PATHWAYS FOR USE IN ALLOGENEIC CELL THERAPIES

(57) Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and uses thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

WO 2023/196980 A1